The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
Abstract
BACKGROUND: This prospective, randomized, double-blind, placebo-controlled, phase III trial assessed the efficacy, safety, and tolerability of mycophenolate mofetil (MMF) as a steroid-sparing agent in patients with myasthenia gravis (MG). METHODS: Patients with acetylcholine receptor antibody-positive class II-IVa MG (MG Foundation of America [MGFA] criteria) taking corticosteroids for at least 4 weeks were randomized to MMF (2 g/day) or placebo for 36 weeks. The primary endpoint was a composite measure defined as achievement of minimal manifestations or pharmacologic remission (MGFA post-intervention status), with reduction of corticosteroid dose on a set schedule. Secondary endpoints included disease severity, quality-of-life scores, and safety. RESULTS: A total of 44% of MMF-treated (n = 88) and 39% of placebo-receiving (n = 88) patients achieved the primary endpoint (p = 0.541). Improvements in mean quantitative MG, MG activities of daily living, and 36-item Short-Form health survey scores were similar in both groups. Numbers of adverse events were similar in both groups. The most commonly reported adverse events in the MMF-treated group were headache (12.5%) and worsening of MG (11.4%), and in the placebo group, worsening of MG (20.5%) and diarrhea (10.2%). CONCLUSIONS: Initiation of mycophenolate mofetil (MMF) treatment was not superior to placebo in maintaining myasthenia gravis (MG) control during a 36-week schedule of prednisone tapering. There were no significant differences in the primary or secondary endpoints between the study groups. MMF was well tolerated and adverse events were consistent with previous studies. Experience from this large, international, multicenter, phase III study employing full MG Foundation of America guidelines will aid the design of future MG studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myasthenia gravis: Recommendations for clinical research standards
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki, A., Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000) · Neurology · doi:10.1212/wnl.55.1.16 · Cited by 1,651
Self-citationMyasthenia gravis activities of daily living profile
Wolfe, G. I., Herbelin, L., Nations, S. P., Foster, B., Bryan, W. W., & Barohn, R. J. (1999) · Neurology · doi:10.1212/wnl.52.7.1487 · Cited by 572
Guidelines for treatment of autoimmune neuromuscular transmission disorders
Skeie, G. O., Apostolski, S., Evoli, A., Gilhus, N. E., Illa, I., Harms, L., Hilton‐Jones, D., Melms, A., Verschuuren, J., & Horge, H. W. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03019.x · Cited by 515
Self-citationA randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis
Palace, J., Newsom-Davis, J., Lecky, B., & Myasthenia Gravis Study Group (1998) · Neurology · doi:10.1212/wnl.50.6.1778 · Cited by 473
Reliability Testing of the Quantitative Myasthenia Gravis Scorea
BAROHN, R. J., McINTIRE, D., HERBELIN, L., WOLFE, G. I., NATIONS, S., & BRYAN, W. W. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb11015.x · Cited by 417
Adverse Gastrointestinal Effects of Mycophenolate Mofetil: Aetiology, Incidence and Management
Behrend, M. (2001) · Drug Safety · doi:10.2165/00002018-200124090-00002 · Cited by 322
Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases
Chaudhry, V., Cornblath, D. R., Griffin, J. W., O’Brien, R., & Drachman, D. B. (2001) · Neurology · doi:10.1212/wnl.56.1.94 · Cited by 259
Immunosuppressive agents for myasthenia gravis
Hart, I. K., Sathasivam, S., & Sharshar, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005224.pub2 · Cited by 212
Self-citationMycophenolate mofetil for myasthenia gravis: An open-label pilot study
Ciafaloni, E., Massey, J. M., Tucker–Lipscomb, B., & Sanders, D. B. (2001) · Neurology · doi:10.1212/wnl.56.1.97 · Cited by 183
Self-citationCorticosteroids for myasthenia gravis
Schneider-Gold, C., Gajdos, P., Toyka, K. V., & Hohlfeld, R. R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002828.pub2 · Cited by 169
Cited by
Gilhus, N. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1602678 · Cited by 1,048
Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. G. M. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0079-y · Cited by 953
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Meriggioli, M. N., & Sanders, D. B. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70063-8 · Cited by 894
Self-citationHoward, J. F., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30369-1 · Cited by 845
Self-citationMyasthenia gravis: an update for the clinician
Sieb, J. P. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12217 · Cited by 283
Metadata
- Authors
- Sanders, D. B., Hart, I. K., Mantegazza, R., Shukla, S. S., Siddiqi, Z. A., De Baets, M. H. V., Melms, A., Nicolle, M. W., Solomons, N., & Richman, D. P.
- Venue
- Neurology
- Published
- 2008-08-05
- Volume
- 71
- Issue
- 6
- Pages
- 400-406
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2058924245
- Cited by
- 318
- References
- 24
- FWCI
- 14.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. https://app.cochat.ai/papers/10.1212/01.wnl.0000312374.95186.cc
- The paper
- Sanders, D. B., Hart, I. K., Mantegazza, R., Shukla, S. S., Siddiqi, Z. A., De Baets, M. H. V., Melms, A., Nicolle, M. W., Solomons, N., & Richman, D. P. (2008). An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. https://doi.org/10.1212/01.wnl.0000312374.95186.cc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.